Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment-Reference-Cited by-同舟云学术

Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment

Published:2017 Issue:1 Volume:241 Page:21-28
ISSN:0040-8727
Container-title:The Tohoku Journal of Experimental Medicine
language:en
Short-container-title:Tohoku J. Exp. Med.

Author:

Inoue Jun¹,Kanno Atsushi²,Wakui Yuta¹,Miura Masahito³,Kobayashi Tomoo⁴,Morosawa Tatsuki¹,Kogure Takayuki¹,Kakazu Eiji¹,Ninomiya Masashi¹,Fujisaka Yasuyuki¹,Umetsu Teruyuki¹,Takai Satoshi¹,Nakamura Takuya¹,Shimosegawa Tooru¹

Affiliation:

1. Division of Gastroenterology, Tohoku University Graduate School of Medicine

2. Department of Gastroenterology, Sendai Red Cross Hospital

3. Department of Gastroenterology, Omagari Kosei Medical Center

4. Department of Hepatology, Tohoku Rosai Hospital

Publisher

Tohoku University Medical Press

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.jstage.jst.go.jp/article/tjem/241/1/241_21/_pdf

Reference22 articles.

1. Aikawa, T., Tsuda, F., Ueno, C., Kikuchi, Y., Ohnishi, H., Nishizawa, T. & Okamoto, H. (2016) Comparison of test results of serogrouping and core region PCR-based genotyping in patients with chronic hepatitis C virus infection: Analysis of inderminate or discrepant cases and identification of a 2b/1b recombinant HCV. Kanzo, 57, 447-456.

2. Chung, H., Ueda, T. & Kudo, M. (2010) Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology, 53, 39-43.

3. El-Shamy, A., Nagano-Fujii, M., Sasase, N., Imoto, S., Kim, S.R. & Hotta, H. (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology, 48, 38-47.

4. Enomoto, H. & Nishiguchi, S. (2015) Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C. World J. Hepatol., 7, 2681-2687.

5. Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., Serrano-Wu, M.H., Langley, D.R., Sun, J.H., O’Boyle, D.R. 2nd., Lemm, J.A., Wang, C., Knipe, J.O., Chien, C., Colonno, R.J., Grasela, D.M., Meanwell, N.A. & Hamann, L.G. (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 465, 96-100.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discrepant Diagnostic Results of Nested Polymerase Chain Reaction-based Genotyping in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection;Internal Medicine;2021-10-15

2. The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment;Internal Medicine;2019-04-01

3. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection;Journal of Gastroenterology;2019-02-18